Several protective effects of losartan confirmed the well-established pathogenic role of AngII in CKD and FSGS, including the reduced AA VSMC (Figure 2C) and podocyte intracellular calcium levels (Figure 4B), improved glomerular capillary blood flow (Figure 4H), increased podocyte number, and reduced glomerulosclerosis and tissue fibrosis (Figure 6, A–C). The gene discussed is AGT; the disease is focal segmental glomerulosclerosis.